Expanding the Potential of CAR T Cell Therapy
The XCART technology platform was designed to utilize an established screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor (BCR) on the surface of an individual patient’s malignant tumor cells. The peptide is then inserted into the antigen-binding domain of a CAR, and a subsequent transduction/transfection process is used to engineer the patient’s T cells into a CAR T format which redirects the patient’s T cells to attack the tumor. Essentially, the XCART screening platform is the inverse of a typical CAR T screening protocol wherein libraries of highly specific antibody domains are screened against a given target. In the case of XCART screening, the target is itself an antibody domain, and hence highly specific by its nature. The XCART technology creates the possibility of personalized treatment of lymphomas utilizing a CAR with an antigen-binding domain that should only recognize, and only be recognized by, the unique BCR of a particular patient’s B-cell Lymphoma. We believe our personalized T cell therapies have the potential to offer cancer patients substantial benefits over the existing standard of care and currently approved CAR T therapies.
Benefits of XCART
Demonstrated proof-of-mechanism and preclinical evidence of target specificity
- XCART targets patient- and tumor-specific neoantigens
- Potential to address multiple tumor types
- Proprietary cell-based screening technology
- Compatible with current up- and down-stream CAR T manufacturing processes
- Applicable to wide range of CAR T constructs
- Enables rapid construction of functional CARs & TCRs
XCART Targets the B-Cell Receptor as a Patient- and Tumor-Specific Neoantigen in B-Cell Lymphoma
An expected result for XCART CAR T therapy is limited off-tumor toxicities, such as B-cell aplasia. Xenetic’s clinical development program will seek to confirm the early preclinical results, and to demonstrate a more attractive safety profile than existing therapies.